The IL-5 inhibitor is already available under the Fasenra brand name for maintenance use in severe eosinophilic asthma, but a new study conducted by researchers at King's College London (KCL ...

Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma, making $1.3 billion in sales last year. It is also being developed for other indications including ...

the drug could also face strong competition from AstraZeneca’s AZN Fasenra, also an IL-5 inhibitor. This AZN drug is currently approved for two indications, namely eosinophilic asthma and EGPA.

Fasenra, our IL-5 monoclonal antibody represents another meaningful opportunity to expand our reach beyond severe eosinophilic asthma and EGPA into COPD with the Phase 3 RESOLUTE trial.

Mepolizumab reduces asthma exacerbations among real-world patients with severe asthma and an eosinophilic phenotype.

Severe eosinophilic is effectively treated with benralizumab, with especially good outcomes in patients with high BEC and high FeNO.

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

Researchers are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.